Mylan CEO Heather Bresch discusses the company's progress from its EpiPen firestorm.
David Ricks, Eli Lilly CEO, weighs in on tax reform priorities, border adjustment tax and drug pricing.
CNBC's Jim Cramer and David Faber weigh in on Carl Icahn stepping up the pressure on Bristol-Myers.
Chester Davis, Association for Accessible Medicines CEO weighs in on highly-priced generic drugs.
CNBC's Meg Tirrell reports the latest on how the fight over drug prices has sparked a civil war in the pharmaceutical industry, with big branded companies in one corner and the generics in the other.
Dave Dorman, CVS Health non-excutive chairman and former AT&T chairman & CEO, discusses the issues around drug pricing and pharmaceutical companies.
Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.
CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.
The new terms set shares of Rite Aid at a maximum of $7 per share and $6.50 minimum, down from the initial $9 Walgreens agreed to purchase.
Novo Nordisk is investing 115 million pounds in a new research center in Britain, undeterred by Brexit.
Shares of Walgreen Boots Alliance and Rite Aid are trading lower after the merger of the two drugstore companies is facing US antitrust concerns.
"Fast Money" trader David Seaburg pitches to the desk why to buy Eli Lilly.
Michael King, JMP Securities senior analyst, weighs in on the biotech sector as President-elect Donald Trump puts the pharmaceutical industry in his cross hairs, calling it "disastrous."
CNBC's Bob Pisani and Art Cashin, of UBS, discuss the market’s reaction to President-elect Donald Trump’s first news conference since Election Day.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing.
CNBC's Meg Tirrell speaks with Express Scripts President & CEO Tim Wentworth on pharmacy benefit managers and drug pricing pressure.
Valeant CEO Joseph Papa speaks to CNBC's Meg Tirrell about the company's turnaround process and drug price increases.
Johnson & Johnson CEO Alex Gorsky speaks to CNBC's Meg Tirrell about his company's expectations for 2017, Donald Trump's impact on the drug industry and potential M&A plans.
A judge ruling blocks Sanofi and partner Regeneron from selling their cholesterol drug, which is a victory for Amgen. CNBC's Meg Tirrell reports.